Autopsy report · NCT02662036

Analgesic Efficacy of Liposomal Bupivacaine vs. Bupivacaine HCL as a Tap Block After Abdominally Based Autologous Breast Reconstruction

“Interim analysis showed that there was no difference between the two drugs”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 2 years before it stopped.
• 70 participants enrolled.
• Results were posted on the registry 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Washington University School of Medicine

Sponsor type

University, hospital or other

Conditions

Mammaplasty

Interventions

Bupivicaine HCL; Liposomal bupivacaine

Participants

70

Sites

1

Countries

United States

Trials that died the same way

• Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
  “Drug was not available.” (66% match in meaning)
• Effectiveness of Periocular Drug Injection in CATaract Surgery
  “Results of interim analysis: stop the trial due to one group being significantly different from the other three groups. Furthermore, shortage of study medication.” (65% match in meaning)
• Iontophoresis in Psoriasis
  “FDA did not provide approval of the use of the drug for the study” (63% match in meaning)
• Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer
  “Drug was no longer available” (63% match in meaning)
• A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma
  “One of the drugs for the study is not commercially available.” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.